Angiotensin II receptor blocker intake associates with reduced markers of inflammatory activation and decreased mortality in patients with cardiovascular comorbidities and COVID-19 disease.

<h4>Aims</h4>Patients with cardiovascular comorbidities have a significantly increased risk for a critical course of COVID-19. As the SARS-CoV2 virus enters cells via the angiotensin-converting enzyme receptor II (ACE2), drugs which interact with the renin angiotensin aldosterone system...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Sebastian Cremer, Lisa Pilgram, Alexander Berkowitsch, Melanie Stecher, Siegbert Rieg, Mariana Shumliakivska, Denisa Bojkova, Julian Uwe Gabriel Wagner, Galip Servet Aslan, Christoph Spinner, Guillermo Luxán, Frank Hanses, Sebastian Dolff, Christiane Piepel, Clemens Ruppert, Andreas Guenther, Maria Madeleine Rüthrich, Jörg Janne Vehreschild, Kai Wille, Martina Haselberger, Hanno Heuzeroth, Arne Hansen, Thomas Eschenhagen, Jindrich Cinatl, Sandra Ciesek, Stefanie Dimmeler, Stefan Borgmann, Andreas Zeiher, LEOSS study group
Formato: article
Lenguaje:EN
Publicado: Public Library of Science (PLoS) 2021
Materias:
R
Q
Acceso en línea:https://doaj.org/article/7e234542cdff42628f85dca9a1f5a0e7
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:7e234542cdff42628f85dca9a1f5a0e7
record_format dspace
spelling oai:doaj.org-article:7e234542cdff42628f85dca9a1f5a0e72021-12-02T20:07:48ZAngiotensin II receptor blocker intake associates with reduced markers of inflammatory activation and decreased mortality in patients with cardiovascular comorbidities and COVID-19 disease.1932-620310.1371/journal.pone.0258684https://doaj.org/article/7e234542cdff42628f85dca9a1f5a0e72021-01-01T00:00:00Zhttps://doi.org/10.1371/journal.pone.0258684https://doaj.org/toc/1932-6203<h4>Aims</h4>Patients with cardiovascular comorbidities have a significantly increased risk for a critical course of COVID-19. As the SARS-CoV2 virus enters cells via the angiotensin-converting enzyme receptor II (ACE2), drugs which interact with the renin angiotensin aldosterone system (RAAS) were suspected to influence disease severity.<h4>Methods and results</h4>We analyzed 1946 consecutive patients with cardiovascular comorbidities or hypertension enrolled in one of the largest European COVID-19 registries, the Lean European Open Survey on SARS-CoV-2 (LEOSS) registry. Here, we show that angiotensin II receptor blocker intake is associated with decreased mortality in patients with COVID-19 [OR 0.75 (95% CI 0,59-0.96; p = 0.013)]. This effect was mainly driven by patients, who presented in an early phase of COVID-19 at baseline [OR 0,64 (95% CI 0,43-0,96; p = 0.029)]. Kaplan-Meier analysis revealed a significantly lower incidence of death in patients on an angiotensin receptor blocker (ARB) (n = 33/318;10,4%) compared to patients using an angiotensin-converting enzyme inhibitor (ACEi) (n = 60/348;17,2%) or patients who received neither an ACE-inhibitor nor an ARB at baseline in the uncomplicated phase (n = 90/466; 19,3%; p<0.034). Patients taking an ARB were significantly less frequently reaching the mortality predicting threshold for leukocytes (p<0.001), neutrophils (p = 0.002) and the inflammatory markers CRP (p = 0.021), procalcitonin (p = 0.001) and IL-6 (p = 0.049). ACE2 expression levels in human lung samples were not altered in patients taking RAAS modulators.<h4>Conclusion</h4>These data suggest a beneficial effect of ARBs on disease severity in patients with cardiovascular comorbidities and COVID-19, which is linked to dampened systemic inflammatory activity.Sebastian CremerLisa PilgramAlexander BerkowitschMelanie StecherSiegbert RiegMariana ShumliakivskaDenisa BojkovaJulian Uwe Gabriel WagnerGalip Servet AslanChristoph SpinnerGuillermo LuxánFrank HansesSebastian DolffChristiane PiepelClemens RuppertAndreas GuentherMaria Madeleine RüthrichJörg Janne VehreschildKai WilleMartina HaselbergerHanno HeuzerothArne HansenThomas EschenhagenJindrich CinatlSandra CiesekStefanie DimmelerStefan BorgmannAndreas ZeiherLEOSS study groupPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 16, Iss 10, p e0258684 (2021)
institution DOAJ
collection DOAJ
language EN
topic Medicine
R
Science
Q
spellingShingle Medicine
R
Science
Q
Sebastian Cremer
Lisa Pilgram
Alexander Berkowitsch
Melanie Stecher
Siegbert Rieg
Mariana Shumliakivska
Denisa Bojkova
Julian Uwe Gabriel Wagner
Galip Servet Aslan
Christoph Spinner
Guillermo Luxán
Frank Hanses
Sebastian Dolff
Christiane Piepel
Clemens Ruppert
Andreas Guenther
Maria Madeleine Rüthrich
Jörg Janne Vehreschild
Kai Wille
Martina Haselberger
Hanno Heuzeroth
Arne Hansen
Thomas Eschenhagen
Jindrich Cinatl
Sandra Ciesek
Stefanie Dimmeler
Stefan Borgmann
Andreas Zeiher
LEOSS study group
Angiotensin II receptor blocker intake associates with reduced markers of inflammatory activation and decreased mortality in patients with cardiovascular comorbidities and COVID-19 disease.
description <h4>Aims</h4>Patients with cardiovascular comorbidities have a significantly increased risk for a critical course of COVID-19. As the SARS-CoV2 virus enters cells via the angiotensin-converting enzyme receptor II (ACE2), drugs which interact with the renin angiotensin aldosterone system (RAAS) were suspected to influence disease severity.<h4>Methods and results</h4>We analyzed 1946 consecutive patients with cardiovascular comorbidities or hypertension enrolled in one of the largest European COVID-19 registries, the Lean European Open Survey on SARS-CoV-2 (LEOSS) registry. Here, we show that angiotensin II receptor blocker intake is associated with decreased mortality in patients with COVID-19 [OR 0.75 (95% CI 0,59-0.96; p = 0.013)]. This effect was mainly driven by patients, who presented in an early phase of COVID-19 at baseline [OR 0,64 (95% CI 0,43-0,96; p = 0.029)]. Kaplan-Meier analysis revealed a significantly lower incidence of death in patients on an angiotensin receptor blocker (ARB) (n = 33/318;10,4%) compared to patients using an angiotensin-converting enzyme inhibitor (ACEi) (n = 60/348;17,2%) or patients who received neither an ACE-inhibitor nor an ARB at baseline in the uncomplicated phase (n = 90/466; 19,3%; p<0.034). Patients taking an ARB were significantly less frequently reaching the mortality predicting threshold for leukocytes (p<0.001), neutrophils (p = 0.002) and the inflammatory markers CRP (p = 0.021), procalcitonin (p = 0.001) and IL-6 (p = 0.049). ACE2 expression levels in human lung samples were not altered in patients taking RAAS modulators.<h4>Conclusion</h4>These data suggest a beneficial effect of ARBs on disease severity in patients with cardiovascular comorbidities and COVID-19, which is linked to dampened systemic inflammatory activity.
format article
author Sebastian Cremer
Lisa Pilgram
Alexander Berkowitsch
Melanie Stecher
Siegbert Rieg
Mariana Shumliakivska
Denisa Bojkova
Julian Uwe Gabriel Wagner
Galip Servet Aslan
Christoph Spinner
Guillermo Luxán
Frank Hanses
Sebastian Dolff
Christiane Piepel
Clemens Ruppert
Andreas Guenther
Maria Madeleine Rüthrich
Jörg Janne Vehreschild
Kai Wille
Martina Haselberger
Hanno Heuzeroth
Arne Hansen
Thomas Eschenhagen
Jindrich Cinatl
Sandra Ciesek
Stefanie Dimmeler
Stefan Borgmann
Andreas Zeiher
LEOSS study group
author_facet Sebastian Cremer
Lisa Pilgram
Alexander Berkowitsch
Melanie Stecher
Siegbert Rieg
Mariana Shumliakivska
Denisa Bojkova
Julian Uwe Gabriel Wagner
Galip Servet Aslan
Christoph Spinner
Guillermo Luxán
Frank Hanses
Sebastian Dolff
Christiane Piepel
Clemens Ruppert
Andreas Guenther
Maria Madeleine Rüthrich
Jörg Janne Vehreschild
Kai Wille
Martina Haselberger
Hanno Heuzeroth
Arne Hansen
Thomas Eschenhagen
Jindrich Cinatl
Sandra Ciesek
Stefanie Dimmeler
Stefan Borgmann
Andreas Zeiher
LEOSS study group
author_sort Sebastian Cremer
title Angiotensin II receptor blocker intake associates with reduced markers of inflammatory activation and decreased mortality in patients with cardiovascular comorbidities and COVID-19 disease.
title_short Angiotensin II receptor blocker intake associates with reduced markers of inflammatory activation and decreased mortality in patients with cardiovascular comorbidities and COVID-19 disease.
title_full Angiotensin II receptor blocker intake associates with reduced markers of inflammatory activation and decreased mortality in patients with cardiovascular comorbidities and COVID-19 disease.
title_fullStr Angiotensin II receptor blocker intake associates with reduced markers of inflammatory activation and decreased mortality in patients with cardiovascular comorbidities and COVID-19 disease.
title_full_unstemmed Angiotensin II receptor blocker intake associates with reduced markers of inflammatory activation and decreased mortality in patients with cardiovascular comorbidities and COVID-19 disease.
title_sort angiotensin ii receptor blocker intake associates with reduced markers of inflammatory activation and decreased mortality in patients with cardiovascular comorbidities and covid-19 disease.
publisher Public Library of Science (PLoS)
publishDate 2021
url https://doaj.org/article/7e234542cdff42628f85dca9a1f5a0e7
work_keys_str_mv AT sebastiancremer angiotensiniireceptorblockerintakeassociateswithreducedmarkersofinflammatoryactivationanddecreasedmortalityinpatientswithcardiovascularcomorbiditiesandcovid19disease
AT lisapilgram angiotensiniireceptorblockerintakeassociateswithreducedmarkersofinflammatoryactivationanddecreasedmortalityinpatientswithcardiovascularcomorbiditiesandcovid19disease
AT alexanderberkowitsch angiotensiniireceptorblockerintakeassociateswithreducedmarkersofinflammatoryactivationanddecreasedmortalityinpatientswithcardiovascularcomorbiditiesandcovid19disease
AT melaniestecher angiotensiniireceptorblockerintakeassociateswithreducedmarkersofinflammatoryactivationanddecreasedmortalityinpatientswithcardiovascularcomorbiditiesandcovid19disease
AT siegbertrieg angiotensiniireceptorblockerintakeassociateswithreducedmarkersofinflammatoryactivationanddecreasedmortalityinpatientswithcardiovascularcomorbiditiesandcovid19disease
AT marianashumliakivska angiotensiniireceptorblockerintakeassociateswithreducedmarkersofinflammatoryactivationanddecreasedmortalityinpatientswithcardiovascularcomorbiditiesandcovid19disease
AT denisabojkova angiotensiniireceptorblockerintakeassociateswithreducedmarkersofinflammatoryactivationanddecreasedmortalityinpatientswithcardiovascularcomorbiditiesandcovid19disease
AT julianuwegabrielwagner angiotensiniireceptorblockerintakeassociateswithreducedmarkersofinflammatoryactivationanddecreasedmortalityinpatientswithcardiovascularcomorbiditiesandcovid19disease
AT galipservetaslan angiotensiniireceptorblockerintakeassociateswithreducedmarkersofinflammatoryactivationanddecreasedmortalityinpatientswithcardiovascularcomorbiditiesandcovid19disease
AT christophspinner angiotensiniireceptorblockerintakeassociateswithreducedmarkersofinflammatoryactivationanddecreasedmortalityinpatientswithcardiovascularcomorbiditiesandcovid19disease
AT guillermoluxan angiotensiniireceptorblockerintakeassociateswithreducedmarkersofinflammatoryactivationanddecreasedmortalityinpatientswithcardiovascularcomorbiditiesandcovid19disease
AT frankhanses angiotensiniireceptorblockerintakeassociateswithreducedmarkersofinflammatoryactivationanddecreasedmortalityinpatientswithcardiovascularcomorbiditiesandcovid19disease
AT sebastiandolff angiotensiniireceptorblockerintakeassociateswithreducedmarkersofinflammatoryactivationanddecreasedmortalityinpatientswithcardiovascularcomorbiditiesandcovid19disease
AT christianepiepel angiotensiniireceptorblockerintakeassociateswithreducedmarkersofinflammatoryactivationanddecreasedmortalityinpatientswithcardiovascularcomorbiditiesandcovid19disease
AT clemensruppert angiotensiniireceptorblockerintakeassociateswithreducedmarkersofinflammatoryactivationanddecreasedmortalityinpatientswithcardiovascularcomorbiditiesandcovid19disease
AT andreasguenther angiotensiniireceptorblockerintakeassociateswithreducedmarkersofinflammatoryactivationanddecreasedmortalityinpatientswithcardiovascularcomorbiditiesandcovid19disease
AT mariamadeleineruthrich angiotensiniireceptorblockerintakeassociateswithreducedmarkersofinflammatoryactivationanddecreasedmortalityinpatientswithcardiovascularcomorbiditiesandcovid19disease
AT jorgjannevehreschild angiotensiniireceptorblockerintakeassociateswithreducedmarkersofinflammatoryactivationanddecreasedmortalityinpatientswithcardiovascularcomorbiditiesandcovid19disease
AT kaiwille angiotensiniireceptorblockerintakeassociateswithreducedmarkersofinflammatoryactivationanddecreasedmortalityinpatientswithcardiovascularcomorbiditiesandcovid19disease
AT martinahaselberger angiotensiniireceptorblockerintakeassociateswithreducedmarkersofinflammatoryactivationanddecreasedmortalityinpatientswithcardiovascularcomorbiditiesandcovid19disease
AT hannoheuzeroth angiotensiniireceptorblockerintakeassociateswithreducedmarkersofinflammatoryactivationanddecreasedmortalityinpatientswithcardiovascularcomorbiditiesandcovid19disease
AT arnehansen angiotensiniireceptorblockerintakeassociateswithreducedmarkersofinflammatoryactivationanddecreasedmortalityinpatientswithcardiovascularcomorbiditiesandcovid19disease
AT thomaseschenhagen angiotensiniireceptorblockerintakeassociateswithreducedmarkersofinflammatoryactivationanddecreasedmortalityinpatientswithcardiovascularcomorbiditiesandcovid19disease
AT jindrichcinatl angiotensiniireceptorblockerintakeassociateswithreducedmarkersofinflammatoryactivationanddecreasedmortalityinpatientswithcardiovascularcomorbiditiesandcovid19disease
AT sandraciesek angiotensiniireceptorblockerintakeassociateswithreducedmarkersofinflammatoryactivationanddecreasedmortalityinpatientswithcardiovascularcomorbiditiesandcovid19disease
AT stefaniedimmeler angiotensiniireceptorblockerintakeassociateswithreducedmarkersofinflammatoryactivationanddecreasedmortalityinpatientswithcardiovascularcomorbiditiesandcovid19disease
AT stefanborgmann angiotensiniireceptorblockerintakeassociateswithreducedmarkersofinflammatoryactivationanddecreasedmortalityinpatientswithcardiovascularcomorbiditiesandcovid19disease
AT andreaszeiher angiotensiniireceptorblockerintakeassociateswithreducedmarkersofinflammatoryactivationanddecreasedmortalityinpatientswithcardiovascularcomorbiditiesandcovid19disease
AT leossstudygroup angiotensiniireceptorblockerintakeassociateswithreducedmarkersofinflammatoryactivationanddecreasedmortalityinpatientswithcardiovascularcomorbiditiesandcovid19disease
_version_ 1718375251939688448